Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 4/20 | 0.52 |
| ▸ | TACR3 | P29371 | 6/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TACR2 | P21452 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6629501 | 0.86 | TACR3 (0.43) | PDE10ATSHRLMNAPOLBDHODH | |
| SCHEMBL14492079 | 0.80 | PDE10A (0.68) | PDE10ATSHRLMNAPOLBDHODH | |
| SCHEMBL6629503 | 0.80 | LMNA (0.52) | LMNATACR3TP53TACR2 | |
| SCHEMBL4776786 | 0.79 | DHODH (0.53) | PDE10ATSHRLMNAPOLBDHODH | |
| SCHEMBL3580968 | 0.79 | PDE10A (0.56) | PDE10ATSHRLMNAPOLBDHODH | |
| SCHEMBL3587309 | 0.78 | PDE10A (0.57) | PDE10ATSHRLMNAPOLBDHODH | |
| SCHEMBL5123788 | 0.77 | DHODH (0.54) | PDE10ATSHRLMNAPOLBDHODH | |
| SCHEMBL4906729 | 0.76 | DHODH (0.50) | PDE10ATSHRLMNAPOLBDHODH | |
| SCHEMBL5437415 | 0.75 | PDE10A (0.57) | PDE10ATSHRLMNAPOLBDHODH | |
| SCHEMBL6957665 | 0.74 | DHODH (0.65) | PDE10ATSHRLMNAPOLBDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377567-B1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2005-12-21 | — | — | EP | claimed |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GLAXOSMITHKLINE SPA | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | KCNQ3, KCNK3, KCNK2 | PDE10A 2668/4885TSHR 891/4885LMNA 2768/4885 |
| US-20050176762-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNQ3, KCNK3, KCNK2 | PDE10A 2668/4885TSHR 891/4885LMNA 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.